Read time: 5 minutes.
The 2026 World Conference on Lung Cancer (WCLC) brought the global thoracic oncology community to Seoul, South Korea from September 12–15. This year's theme, “Science Without Boundaries: Uniting the World Against Thoracic Cancer,” was particularly fitting for early-stage lung cancer, where treatment before and after surgery is rapidly evolving through multinational studies.
Here are the conference highlights, organized by immunotherapy, targeted therapy, surgery, and supportive care.
Immunotherapy Before and After Surgery
Does perioperative atezolizumab improve survival? Not quite
The phase 3 IMpower030 trial tested the combination of immunotherapy (atezolizumab) plus chemotherapy before surgery, followed by atezolizumab after surgery, against placebo plus chemotherapy.
It enrolled patients with stage IIB–IIIB disease without EGFR or ALK alterations. Median event-free survival was 62.8 months with atezolizumab versus 34.9 months with placebo, but the difference did not reach statistical significance. More patients receiving atezolizumab had no remaining cancer at surgery (pathologic complete response, 29.6% vs 8.5%). The placebo group did unusually well compared with past trials, which may explain the result. Other trials have already made immunotherapy around surgery a standard of care.
Can borderline-resectable tumors still be surgically removed? Yes – with multidisciplinary care
The MDT-BRIDGE study treated patients with stage IIB–IIIB disease, about one-third of whom had tumors considered borderline for surgery. After two cycles of the immunotherapy, durvalumab, plus chemotherapy, a multidisciplinary team of oncologists, surgeons, radiation oncologists, and pathologists reassessed each patient. Overall, 74.6% had surgery, and 96.2% of those had their tumor completely removed. Patients who could not have surgery received chemoradiation instead.
Can a cancer vaccine boost treatment before surgery? Early signs say yes
BNT116 is an investigational mRNA cancer vaccine that trains the immune system to recognize proteins commonly found on lung cancer cells. A phase 1 study of 20 patients reported that BNT116 plus the immunotherapy, cemiplimab, and chemotherapy shrank tumors in 65% of patients before surgery, with no cancer growth during treatment. Of 15 patients with surgical results, 53% had a major pathologic response, including 40% with no remaining cancer. Two-thirds developed immune responses to the vaccine's targets.
Does adding focused radiation to the treatment regimen help? Possibly
In the SACTION01 trial, researchers added stereotactic body radiotherapy (SBRT), a precise, high-dose radiation given in three sessions, to the immunotherapy, tislelizumab, plus chemotherapy before surgery. After a median follow-up of nearly four years, 65% of patients were alive without their cancer returning, and 79% were alive overall. A phase 3 trial of 360 patients is now underway.
Can PET scans predict who responds to neoadjuvant immunotherapy? Yes
In patients from the NADIM II and REAL-NADIM trials, changes on PET/CT scans after nivolumab (immunotherapy) plus chemotherapy predicted who would have no remaining cancer at surgery. Patients whose tumors showed a deeper metabolic response (more than 95% reduction) also lived longer without progression. Though these findings need confirmation in prospective studies, they suggest that PET/CTs may be useful to gauge response in this setting.
Targeted Therapy for Early-Stage Disease
Can targeted therapy shrink ALK-positive tumors before surgery? Yes
NAUTIKA1 is a phase 2 study testing targeted therapies before surgery in patients whose tumors carry specific driver mutations. In the ALK-positive cohort, patients with stage IB–IIIB disease took alectinib for eight weeks before surgery. Tumors shrank in 60% of patients, and 56% had a major pathologic response, including 19% with no remaining cancer. Surgery completely removed the tumor in 95% of patients. At two years, 90% of patients were alive without their cancer returning. Patients who cleared tumor DNA from their blood (ctDNA) before surgery tended to do better. Neoadjuvant alectinib (before surgery) may be a promising approach for ALK-positive lung cancer.
What about neoadjuvant treatment for KRAS G12C? Early signs are promising
In the KRAS G12C group of the NAUTIKA1 study, tumors shrank in 55% of patients who took divarasib, a next-generation KRAS G12C inhibitor, for eight weeks before surgery. Among the patients who had surgery, 42% had a major pathologic response, and 16% had no remaining cancer. Every patient who had surgery had their tumor completely removed, with no surgical complications. Tumors shrank regardless of PD-L1 level or co-mutations like STK11, which often make immunotherapy less effective.
Surgery and Supportive Care
Does checking enough lymph nodes during surgery matter? Yes
During lung cancer surgery, surgeons remove or sample nearby lymph nodes to see whether the cancer has spread, which affects staging and whether more treatment is needed. Several guidelines recommend different minimum numbers of lymph node areas to check. Using the IASLC global database of more than 31,000 patients, researchers found that patients whose surgery met any of these guidelines lived longer than those whose surgery met none. No single guideline clearly outperformed the others. Thorough lymph node checks also found more hidden spread, leading more patients to receive additional treatment after surgery. Therefore, lymph node sampling is critical for optimal outcomes after surgery.
Can prehabilitation before surgery boost the immune system? Possibly
Prehabilitation means preparing the body for surgery through exercise and nutrition. In a substudy of the MMP-LUNG randomized trial, patients with resectable lung cancer received no intervention, nutritional supplements alone, or supplements plus supervised exercise. Patients in the combined program improved their physical fitness, had more circulating immune cells, and showed lower markers of inflammation before surgery. The study suggests that overall health status may support the immune system as one prepares for surgery. Whether these immune changes lead to better outcomes, especially with immunotherapy, still needs to be studied.
Wrapping Up
WCLC 2026 showed early-stage lung cancer care is becoming more complex and personalized. From immunotherapy and cancer vaccines to targeted therapies, the horizon is full of promise. While tools like PET scans and blood-based ctDNA may soon help guide who needs more or less treatment. Stay tuned for more updates on progress in early-stage lung cancer research.
More World Conference on Lung Cancer 2026 Coverage:
